US-based clinical-stage drug development company Karuna Pharmaceuticals has begun its proof-of-concept study of KarXT for Alzheimer’s disease by dosing its first patient.

KarXT features a combination of xanomeline, which acts as a muscarinic acetylcholine receptor agonist, and trospium chloride, a muscarinic receptor antagonist that has been shown not to enter the central nervous system (CNS).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The muscarinic receptors in the nervous system fuse with the acetylcholine (a neurotransmitter) and an activation of muscarinic receptors outside of the brain leads to side effects such as GI adverse events.

The randomised, double-blind, multiple-dose trial will study the tolerability of KarXT compared to xanomeline alone in 70 healthy individuals.

"By combining xanomeline with trospium chloride, we aim to unlock the therapeutic potential of M1/M4 agonists and address the significant unmet need in treating these disorders."

The volunteers will undergo an in-clinic treatment for nine days. After a two-day run-in period with trospium alone, the volunteers will be administered with xanomeline and either trospium chloride or placebo.

See Also:

Karuna CEO Andrew Miller said: “In clinical studies, xanomeline has shown robust efficacy in people with schizophrenia and in people with Alzheimer’s disease, demonstrating the immense potential of targeting the M1/M4 muscarinic acetylcholine receptors; however, the muscarinic field has been stymied by tolerability concerns caused by activation of muscarinic receptors in peripheral tissues.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“By combining xanomeline with trospium chloride, we aim to unlock the therapeutic potential of M1/M4 agonists and address the significant unmet need in treating these disorders.”

The company is expecting to report the top-line results of the proof-of-concept study by the end of this year.